Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown

Research output: Contribution to journalArticlepeer-review

Abstract

Over the past few years our understanding of the importance of adaptive immunity in acute coronary syndromes (ACS) has considerably increased. Profound abnormalities have been observed in specific subsets of CD4+T cells, including type 1 helper T (Th1) cells,CD4+CD28nullT cells, and naturally occurring regulatory T cells (Treg cells). Recently a new lineage of CD4+T cells, type 17 helper T (Th17) cells producing the signature cytokines interleukin (IL)-17, IL-21, and IL-22, has been identified. This has fundamentally changed the Th1/Th2 dichotomy paradigm.
Original languageEnglish
Pages (from-to)556-559
Number of pages4
JournalEuropean Heart Journal
Volume34
DOIs
Publication statusPublished - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Acute Coronary Syndromes
  • Atherosclerosis
  • Immune system
  • Interleukin-17

Fingerprint

Dive into the research topics of 'Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown'. Together they form a unique fingerprint.

Cite this